LFG
CSTL icon

Larson Financial Group’s Castle Biosciences CSTL Stock Holding History

Larson Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Hold
1
– – ﹤0.01% 3573
2025
Q4 		$39 Hold
1
– – ﹤0.01% 3391
2025
Q3 		$23 Buy
+1
New +$20 ﹤0.01% 3389
2025
Q1 		– Sell
-12
Closed -$320 – 3100
2024
Q4 		$320 Buy
+12
New +$365 ﹤0.01% 2314

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Larson Financial Group's CSTL Position: Q1 2026 in Review

Larson Financial Group held its Castle Biosciences (CSTL) position steady in Q1 2026 at 1 share worth $25. The position accounts for ﹤0.01% of the portfolio, ranked #3573.

Larson Financial Group first reported a position in CSTL in Q4 2024 and has held it in 4 quarters since. The position peaked at $320 in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Larson Financial Group held 1 share of Castle Biosciences worth $25 as of Q1 2026.
  • Larson Financial Group left its Castle Biosciences share count unchanged in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3573 holding.
  • Larson Financial Group first reported a position in Castle Biosciences in Q4 2024 and has held it in 4 quarters since.
  • Larson Financial Group's Castle Biosciences position peaked at $320 in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.